Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Geron Corporation
ClinicalTrials.gov Identifier:
NCT01137968
First received: June 3, 2010
Last updated: October 10, 2013
Last verified: October 2013
  Purpose

The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.

Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.


Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: imetelstat
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)

Resource links provided by NLM:


Further study details as provided by Geron Corporation:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ] [ Designated as safety issue: No ]
    Defined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.


Secondary Outcome Measures:
  • Objective response [ Time Frame: Occurring post randomization through end of study period (8 mos. after the last participant is randomized) ] [ Designated as safety issue: No ]
    Objective response (partial response plus complete response) occurring post-randomization as determined by the Investigator's assessment according to RECIST criteria using post-induction tumor dimensions as a baseline.

  • Time to all-cause mortality [ Time Frame: From the date of randomization through end of study period (8 mos. after the last participant is randomized) ] [ Designated as safety issue: No ]
    Defined as the time from the date of radomization to death from any cause during the study period.

  • Safety and tolerability [ Time Frame: From the date of randomization through the end of the study period (8 mos. after the last participant is randomized) ] [ Designated as safety issue: Yes ]
    Safety and tolerability will be assessed by the incidence, nature, and severity of adverse events, laboratory abnormalities, and vital signs.


Estimated Enrollment: 96
Study Start Date: May 2010
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: imetelstat plus standard of care
imetelstat plus standard of care (bevacizumab or observation)
Drug: imetelstat
9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
Other Name: GRN163L
Drug: Bevacizumab
Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Other Name: Avastin
Standard of care
Bevacizumab or observation
Drug: Bevacizumab
Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Other Name: Avastin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent.
  • Ability and willingness to comply with requirements of the study protocol.
  • Male or female, age 18 or over.
  • Histologically or cytologically confirmed diagnosis of NSCLC
  • Stage IV (using the 7th edition of AJCC, or wet IIIb / IV using the 6th edition), or recurrent locally advanced disease not amenable to radiation or surgery with curative intent and not amenable to concurrent chemoradiation.
  • Patients have completed four to six cycles of platinum-based chemotherapy doublet for first line, advanced NSCLC, with no evidence of disease progression according to RECIST version 1.1. Adjuvant chemotherapy greater than one year prior to progression is allowed.
  • Patients are willing and able to continue treatment with bevacizumab, if they received it with their platinum based chemotherapy.
  • ECOG performance status 0-1
  • Adequate bone marrow reserve as measured by ANC ≥ 1500/mm3, hemoglobin

    ≥ 9 g/dL, platelet count ≥ 75,000 μL. Must be measured ≥ 1 week after last transfusion of blood products and/or last dose of hematopoietic growth factor.

  • Prothrombin time (PT) or INR or aPTT ≤ 1.5 x ULN.
  • Serum creatinine < 1.5 mg/dL or creatinine clearance > 45 mL/min.
  • Urinalysis with < 2+ protein or urinary excretion of < 2 g of protein/day (for patients to receive bevacizumab).
  • AST (SGOT) and ALT (SGPT) < 2.5 x the ULN, (AST (SGOT) and ALT (SGPT) < 5 x the ULN if documented liver metastases).
  • Serum bilirubin < 2.0 mg/dL (patients with Gilbert's syndrome: serum bilirubin < 3 x ULN).
  • Alkaline phosphatase < 2.5 x ULN (patients with documented liver or bone metastases, alkaline phosphatase ≤ 5 x ULN).
  • No other obvious related major organ toxicities which would compromise the patient's ability to participate in a clinical trial of a novel agent.
  • Patients may have received prior radiation therapy for local or locally advanced disease providing that any clinically significant adverse effects associated with prior therapy have recovered to Grade 1 or less.
  • Women of childbearing potential must have a negative serum pregnancy test and agree to use effective birth control during and for 12 weeks after the last treatment with imetelstat.
  • Males must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last treatment with imetelstat.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from screening and study entry:

  • Patients who are not eligible for induction therapy with a platinum based chemotherapy doublet.
  • Patients who have received, or are scheduled to receive pemetrexed or erlotinib as maintenance therapy.
  • Patients receiving bevacizumab must not have a recent history of hemoptysis ≥ ½ teaspoon of red blood or history of ≥ 2 g/24 hr urine protein while receiving prior bevacizumab, or squamous cell histology.

Patients will be excluded from being randomized if any of the following criteria apply:

  • Last dose of induction chemotherapy < 21 days prior to randomization or > 42 days prior to randomization
  • History of pulmonary hemorrhage (> 1 teaspoon) within the 4 weeks prior to randomization.
  • Anti-platelet therapy within 2 weeks prior to randomization, other than low dose aspirin prophylaxis therapy.
  • Therapeutic anticoagulation therapy except for low dose warfarin (e.g., 1 mg by mouth per day).
  • Radiation therapy within 3 weeks prior to randomization (palliative radiation therapy is allowed, provided that sites of bone marrow production, i.e. iliac crests are not in the radiation field)
  • Major surgery within 4 weeks prior to first study drug administration (central line placement is allowed)
  • Active central nervous system (CNS) metastatic disease. Patients with stable CNS disease following completion of radiation therapy and/or surgery are eligible.
  • Any other active malignancy
  • Active or chronically recurrent bleeding (e.g., active peptic ulcer disease)
  • Clinically significant infection
  • Active autoimmune disease requiring immunosuppressive therapy
  • Clinically significant cardiovascular disease or condition including:

    • Congestive heart failure (CHF) requiring therapy
    • Need for anti-arrhythmic therapy for a ventricular arrhythmia
    • Severe conduction disturbance
    • Angina pectoris requiring therapy
    • Medically uncontrolled hypertension per the Investigator's discretion
    • Myocardial infarction within 6 months prior to first study drug administration
    • New York Heart Association Class II, III, or IV cardiovascular disease
  • Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01137968

  Hide Study Locations
Locations
United States, Alabama
Achieve Clinical Research, Llc
Birmingham, Alabama, United States, 35216
Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
United States, California
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States, 92801
Cancer Care Associates of Fresno Medical Group Inc
Fresno, California, United States, 93720
St. Joseph's Hospital
Orange, California, United States, 92868
Kaiser Permanente Medical Center
Vallejo, California, United States, 94589
United States, Colorado
University of Colorado Denver School of Medicine
Aurora, Colorado, United States, 80045
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
Integrated Community Oncology Network
Jacksonville, Florida, United States, 32256
H. Moffitt Lee Cancer Center
Tampa, Florida, United States, 33612
United States, Illinois
Ingalls Memorial Hospital
Harvey, Illinois, United States, 60426
United States, Kansas
Cancer Center of Kansas
Wichita, Kansas, United States, 67214
United States, Kentucky
Montgomery Cancer Center
Mt. Sterling, Kentucky, United States, 40353
United States, Maryland
Auerbach Hematology Oncology
Baltimore, Maryland, United States, 21237
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Montana
Hematology Oncology Centers
Billings, Montana, United States, 59101
United States, North Carolina
Blumenthal Cancer Center
Charlotte, North Carolina, United States, 28204
United States, Oregon
Kaiser Northwest
Portland, Oregon, United States, 97227
United States, South Carolina
South Carolina Oncology Associates
Columbia, South Carolina, United States, 29210
United States, Tennessee
The Jones Clinic
Germantown, Tennessee, United States, 38138
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Scott and White Memorial Hospital (Texas A & M)
Temple, Texas, United States, 76508
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Canada, Quebec
Hôpital Charles Lemoyne
Greenfield Park, Quebec, Canada, J4V 2H1
Hospital Notre-Dame
Montreal, Quebec, Canada, H2L 4M1
Germany
Krankenhaus Grosshansdorf
Grosshansdorf, Hamburg, Germany, 22927
Asklepios Klinik Gauting GmbH
Gauting, Munich, Germany, 82131
Klinikum rechts der Isar der TU München
Munchen, Munich, Germany
Krankenhaus Nordwest
Frankfurt, Germany, 60488
Universitaetsklinikum Mainz
Mainz, Germany, 55131
Sponsors and Collaborators
Geron Corporation
Investigators
Study Director: Ted Shih, PharmD Geron Corporation
Principal Investigator: Joan Schiller, MD University of Texas
  More Information

No publications provided

Responsible Party: Geron Corporation
ClinicalTrials.gov Identifier: NCT01137968     History of Changes
Other Study ID Numbers: CP14B012
Study First Received: June 3, 2010
Last Updated: October 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Geron Corporation:
imetelstat
imetelstat sodium
GRN163L
telomerase inhibitor
telomerase inhibition
maintenance therapy
non-small cell lung cancer
relapsed non-small cell lung cancer
advanced non-small cell lung cancer
NSCLC, cancer stem cells
Bevacizumab
post induction chemotherapy

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 28, 2014